Oropharynx cancer throat cancer
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with histological proven squamous cell carcinoma of the orpharynx scheduled for (chemo)radiotherapy.
Exclusion criteria
Exclusion criteria: -Patients with recurrence of previously confirmed head and neck squamous cell carcinoma. -Patients undergoing any other treatment option for the primary tumor like surgery. -Patients with other types of head and neck malignancies: lymphatic neoplasms, esophageal malignancies, thyroid cancer, lip cancer, skin cancers and other malignancies not originating from the pharynx. -Having any physical or mental status that interferes with the informed consent procedure. -Contraindications for MRI (e.g. claustrophobia, arterial clips in central nervous system)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study parameters: Functional changes (ADC values) The diffusion-weighted images will be analyzed on a PACS-station. The ADC changes (*ADCN ) in % for each lesion between the baseline and the time point of response evaluation are calculated using the formula: *ADC4=[(ADC4 -ADCB)/ADCB]*100 *ADCa=[(ADCa -ADCB)/ADCB]*100 ADCB represents pretreatment ADC-value ADC4 represents the ADC-value at the 4th week of treatment, and ADCa represents the ADC-value three week after treatment. structural (volume) changes Location, volume and size of primary tumor and enlarged lymph nodes will be measured on the T2-weighted and contrast-enhanced T1-weighted images. | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secundary parameters | — |
Countries
Netherlands
Outcome results
None listed